REGENXBIO Inc. — 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. The filing also reports unaudited fourth-quarter results. REGENXBIO is a clinical-stage gene-therapy company that develops its own candidates and licenses its NAV AAV-vector platform to partners. Its pipeline comprised 5 internal and 23 partnered candidates at year-end.
Financial performance and liquidity
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $7.6 million | $6.1 million |
| Operating expenses | $30.7 million | $9.8 million |
| Operating loss | $23.1 million | $3.7 million |
| Net loss | $22.8 million | $4.0 million |
| Operating cash flow | $(22.5) million | $(2.4) million |
| Cash, cash equivalents and marketable securities at year-end | $216.4 million | $1.1 million |
| Total liabilities at year-end | $4.6 million | $9.2 million |
Revenue was primarily licensing revenue: $7.0 million from licenses, including $2.0 million reported as related-party revenue, alongside $0.3 million in grant revenue and $0.3 million in reagent sales. Gross margin is not separately presented; the company remained loss-making, with operating expenses substantially exceeding revenue. No debt instruments were outstanding at December 31, 2015. Working capital was $113.8 million.
Fourth-quarter revenue was $4.4 million and net loss was $5.2 million, compared with third-quarter revenue of $1.1 million and net loss of $7.3 million. Quarterly results can fluctuate with license payments and expenses.
Changes versus prior year
- Revenue rose $1.5 million, mainly reflecting increased license fees and option exercises, including seven new commercial licenses in 2015; lower grant revenue partly offset the increase.
- Research and development expense increased to $17.3 million from $5.0 million, as the company expanded preclinical, manufacturing and clinical-material work, particularly for RGX-111, RGX-121 and RGX-314.
- General and administrative expense rose to $11.9 million from $3.9 million, reflecting increased staffing, professional fees and public-company costs.
- Net loss widened to $22.8 million from $4.0 million. The company completed a $145.2 million net-proceeds IPO and raised additional capital through preferred-stock financings; preferred shares converted to common stock at the IPO.
Outlook, risks and notable items
- Management expected year-end liquidity to fund operations and capital requirements into 2018, including Phase I/II trials for RGX-501 and RGX-111 and an IND filing for RGX-314. Management cautioned that estimates rely on assumptions and additional funding may ultimately be needed.
- RGX-501’s IND for HoFH was active; the company expected to start a Phase I/II trial in the first half of 2016. It expected to file an IND for RGX-111 for MPS I in the first half of 2016 and begin its trial in mid-2016; an IND for wet AMD candidate RGX-314 was expected in the second half of 2016. These are forward-looking plans, not achieved milestones in this reporting period.
- Three partner-led NAV-vector clinical trials were ongoing at year-end, including programs for SMA Type I, MPS IIIA and hemophilia B. No company or licensee product using the platform had been commercialized.
- Revenue is volatile and concentrated: three customers accounted for approximately 79% of 2015 revenue. Future licensing revenue depends on partners’ development and commercial success; management expected grant revenue to decline and was not seeking further grants.
- Key risks include clinical and regulatory uncertainty in gene therapy, safety and immune-response concerns, manufacturing scale-up and reliance on third parties, competition, intellectual-property and licensing dependencies, and the need for future capital. The company’s lead internal candidates were at an early development stage.
- Management reported that disclosure controls were not effective at year-end because of two material weaknesses: contract-review controls and insufficient financial-reporting resources and segregation of duties. Remediation was underway but not yet complete. The auditor issued an unqualified opinion on the financial statements.
- Unusual financial items included $2.9 million of stock-based compensation, a $0.7 million unrealized loss on available-for-sale securities recorded in other comprehensive loss, and settlement of FoxKiser-related debt and service fees through preferred-stock conversion and cash payment.
Investor verification priorities
- Track whether planned IND, trial-start and enrollment milestones occurred on schedule, and review subsequent safety and efficacy data.
- Confirm cash consumption, investment liquidity and the assumptions underlying management’s runway estimate; assess potential financing and dilution needs.
- Review the customer and licensee concentration, partner program progress, and any changes to contingent milestones, royalties or license agreements.
- Check whether the two material weaknesses were fully remediated and whether subsequent filings report effective controls.
- Assess manufacturing readiness and dependence on WuXi, Penn and other external providers, alongside patent coverage and any disputes or license restrictions.